A Phase I pharmacokinetic assessment of zavacorilant softgel capsule formulation, including dose proportionality and food effect in healthy subjects
Latest Information Update: 10 Jun 2024
At a glance
- Drugs Zavacorilant (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease
- Focus Pharmacokinetics
- Acronyms QSC301567
- Sponsors Corcept Therapeutics
Most Recent Events
- 29 Mar 2024 Status changed from not yet recruiting to recruiting.
- 27 Mar 2024 New trial record